Примери за използване на Was similar to that seen на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The safety profile was similar to that seen in adults.
In general, the adverse reaction profile of duloxetine in children and adolescents was similar to that seen for adults.
The decrease seen with Leganto was similar to that seen with pramipexole(2.8 h).
In clinical trials of 48 weeks treatment and24 weeks follow-up, the safety profile for Pegasys in CHB was similar to that seen in CHC.
The pattern of activity was similar to that seen when the animals were fully conscious- except signals were up to eight times stronger.
The incidence of dystonia in paediatric clinical trials using a gradual up-titration was similar to that seen in adult trials.
The incidence of increased IOP(24.9%) was similar to that seen following the first injection and likewise returned to baseline by open-label day 180.
Elderly In a study conducted inelderly subjects with schizophrenia, the safety profile was similar to that seen in non-elderly subjects.
The overall safety profile in subjects with severe renal impairment was similar to that seen in prior Phase 3 studies in subjects without severe renal impairment, except that a greater proportion of subjects required intervention due to ribavirin-associated decreases in serum haemoglobin.
The pharmacokinetic profile of rituximab when administered as 6 infusions of 375 mg/m2 in combination with 6 cycles of CHOP chemotherapy was similar to that seen with rituximab alone.
Among patients who were naive to IOP therapy(10 patients),the efficacy of AZOPT was similar to that seen previously in adults, with mean IOP reductions from baseline ranging up to 5 mmHg.
In one short-term and two longer-term studies with paliperidone prolonged-release tablets conducted in adolescents 12 years and older with schizophrenia,the overall safety profile was similar to that seen in adults.
In cardiovascular high risk population the adverse reaction profile was similar to that seen in the other phase 3a trials(described in section 5.1).
In clinical trials of 48 week treatment and24 weeks follow-up, the safety profile for Pegasys in chronic hepatitis B was similar to that seen in chronic hepatitis C.
In the 96 week analysis, the safety profile of PREZISTA/ritonavir 800/100 mg once daily in treatment-naïve subjects was similar to that seen with PREZISTA/ritonavir 600/100 mg twice daily in treatment-experienced subjects except for nausea which was observed more frequently in treatment-naïve subjects.
The overall rate of thrombotic events in patients treated with Arixtra was significantly less than in patients treated with placebo orenoxaparin(for patients undergoing leg surgery), and was similar to that seen with enoxaparin(treatment of DVT), dalteparin or unfractionated heparin.
Clinical improvement, including onset of action within 2 weeks with LIFMIOR 25 mg, was similar to that seen in the previous trials and was maintained for up to 24 months.
Clinical improvement, including onset of action within 2 weeks with etanercept 25 mg, was similar to that seen in the previous trials and was maintained for up to 24 months.
This was below the predefined number needed to show effectiveness(which is one infection per year), and was similar to that seen with other licensed human normal immunoglobulin products.
This is similar to that seen in a sulphonylurea active comparator group.
This is similar to that seen in most of the earlier studies.
In children 2 years of age and older,the nature of the safety profile is similar to that seen in adults(see Table in section b).
The pharmacodynamic profile of insulin lispro in children is similar to that seen in adults.
The adverse eventprofile associated with overdose, as seen during post-marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.
The absolute bioavailability of Pegasys is 84% and is similar to that seen with interferon alfa-2a.
The safety profile of Norvir in children 2 years of age and older is similar to that seen in adults.
Paediatric populations The safety profile of ritonavir in children 2 years of age and older is similar to that seen in adults.
Studies show that survival following treatment with Cresemba is similar to that seen with other treatments.
Limited published data suggest that the safety profile in adolescents from 12 to 16 years of age receiving AVONEX 30 micrograms IM once per week is similar to that seen in adults.
The results of this study suggest that the safety profile in children(2 to 11 years old) and in adolescents(12 to 17 years old) receiving Rebif 22 micrograms or44 micrograms subcutaneous three times per week is similar to that seen in adults.